このページの翻訳は実験的なもので、現在開発中です。お待ちしております
BeiGene マネジメント
マネジメント 基準チェック /24
BeiGene'sの CEO はJohn Oylerで、 Jan2010年に任命され、 の在任期間は 14.58年です。 の年間総報酬は$ 18.93Mで、 4.6%給与と95.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の3.41%を直接所有しており、その価値は$ 695.59M 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と4.6年です。
主要情報
John Oyler
最高経営責任者
US$18.9m
報酬総額
| CEO給与比率 | 4.6% |
| CEO在任期間 | 14.7yrs |
| CEOの所有権 | 3.9% |
| 経営陣の平均在職期間 | 2.4yrs |
| 取締役会の平均在任期間 | 4.7yrs |
経営陣の近況
Recent updates
BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat
Aug 22Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts
Aug 14
BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth
Aug 09BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)
Jun 21We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation
May 30Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?
Apr 21BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price
Jan 31Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money
Oct 16Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?
Jul 11Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt
Jun 19Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)
Apr 17A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)
Mar 24CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$524m |
| Mar 31 2024 | n/a | n/a | -US$784m |
| Dec 31 2023 | US$19m | US$871k | -US$882m |
| Sep 30 2023 | n/a | n/a | -US$959m |
| Jun 30 2023 | n/a | n/a | -US$2b |
| Mar 31 2023 | n/a | n/a | -US$2b |
| Dec 31 2022 | US$18m | US$800k | -US$2b |
| Sep 30 2022 | n/a | n/a | -US$2b |
| Jun 30 2022 | n/a | n/a | -US$2b |
| Mar 31 2022 | n/a | n/a | -US$2b |
| Dec 31 2021 | US$17m | US$740k | -US$1b |
| Sep 30 2021 | n/a | n/a | -US$1b |
| Jun 30 2021 | n/a | n/a | -US$1b |
| Mar 31 2021 | n/a | n/a | -US$1b |
| Dec 31 2020 | US$14m | US$696k | -US$2b |
| Sep 30 2020 | n/a | n/a | -US$2b |
| Jun 30 2020 | n/a | n/a | -US$1b |
| Mar 31 2020 | n/a | n/a | -US$1b |
| Dec 31 2019 | US$13m | US$675k | -US$949m |
| Sep 30 2019 | n/a | n/a | -US$829m |
| Jun 30 2019 | n/a | n/a | -US$665m |
| Mar 31 2019 | n/a | n/a | -US$737m |
| Dec 31 2018 | US$28m | US$650k | -US$674m |
| Sep 30 2018 | n/a | n/a | -US$505m |
| Jun 30 2018 | n/a | n/a | -US$243m |
| Mar 31 2018 | n/a | n/a | -US$147m |
| Dec 31 2017 | US$10m | US$515k | -US$93m |
報酬と市場: Johnの 総報酬 ($USD 18.93M ) は、 US市場 ($USD 13.21M ) の同規模の企業の平均を上回っています。
報酬と収益: Johnの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
John Oyler (56 yo)
14.7yrs
在職期間
US$18,925,730
報酬
Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 14.7yrs | US$18.93m | 3.91% $ 883.9m | |
| President & COO | 6.3yrs | US$11.00m | 0.055% $ 12.5m | |
| Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder | 14.7yrs | US$4.42m | 0.82% $ 186.3m | |
| General Counsel & Senior VP | 2.2yrs | US$4.05m | 0.018% $ 4.1m | |
| Global Head of R&D | no data | US$7.32m | 0.13% $ 29.1m | |
| CFO & Principal Financial Officer | less than a year | データなし | データなし | |
| VP & Chief Accounting Officer | less than a year | データなし | 0.0033% $ 754.7k | |
| Head of Investor Relations | no data | データなし | データなし | |
| Chief Compliance Officer | less than a year | データなし | データなし | |
| Senior VP & Head of Public Affairs - Greater China | 3.7yrs | データなし | データなし | |
| Senior Vice President of Strategy & Corporate Development | 1.6yrs | データなし | データなし | |
| Senior VP & Chief Medical Officer for Solid Tumors | 2.6yrs | データなし | データなし |
2.4yrs
平均在職期間
53.5yo
平均年齢
経験豊富な経営陣: BGNEの経営陣は 経験豊富 であると考えられます ( 2.4年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 13.9yrs | US$18.93m | 3.91% $ 883.9m | |
| Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder | 8.6yrs | US$4.42m | 0.82% $ 186.3m | |
| Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board | 3.4yrs | データなし | データなし | |
| Independent Non-Executive Director & Member of the Scientific Advisory Committee | 9.4yrs | US$481.92k | 0.0034% $ 763.8k | |
| Independent Non-Executive Director | 11.6yrs | US$480.80k | 0.20% $ 44.2m | |
| Independent Non-Executive Director & Member of Scientific Advisory Committee | 4.1yrs | US$501.55k | 0.0022% $ 488.1k | |
| Independent Non-Executive Director | 4.7yrs | US$513.15k | 0.0027% $ 612.4k | |
| Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director | 2.6yrs | US$491.67k | 0.0021% $ 483.6k | |
| Independent Non-Executive Director | less than a year | データなし | 0% $ 0 | |
| Independent Lead Director | 9.9yrs | US$487.05k | 0.0034% $ 763.8k | |
| Member of Scientific Advisory Board & Independent Non-Executive Director | 2.6yrs | US$510.55k | 0.0021% $ 483.6k |
4.7yrs
平均在職期間
65yo
平均年齢
経験豊富なボード: BGNEの 取締役会 は 経験豊富 であると考えられます ( 4.6年の平均在任期間)。